CDNACareDx, Inc.

Price: $85.42 | Today's Change: +19.44%

What Happened

CareDx, Inc. (CDNA) filed its Form 10-Q for the third quarter of fiscal year 2026 with the SEC on October 29, 2026, revealing quarterly revenue of $271.4 million — a figure that underscores the company's substantial growth from the $11.6 million in revenue recorded as far back as Q1 FY2018. Despite the strong top-line result, the company reported a net loss of $10.4 million and an operating loss of $24.7 million for Q3 FY2026. Basic and diluted earnings per share both came in at -$0.32.

Why It Matters

For investors, the Q3 FY2026 results present a mixed but noteworthy picture:

• Revenue scale: $271.4 million in quarterly revenue signals that CareDx has built a meaningfully large commercial operation in transplant diagnostics and patient management solutions.
• Profitability gap: An operating loss of $24.7 million indicates that the company is still spending materially more than it earns from operations — a key risk factor to monitor as the business matures.
• EPS: The -$0.32 loss per share (both basic and diluted) gives investors a per-share anchor to track profitability progress quarter over quarter.
• Stock reaction: The 19.44% surge in CDNA's share price today, reaching $85.42, suggests the market interpreted these results — or accompanying guidance or commentary in the filing — as meaningfully better than prior expectations. It is worth noting that this move takes the stock well above the $62.00 price target outlined in StockWatch's initiating coverage published on September 24, 2026.

Analysis

The scale of today's stock move — nearly one-fifth of CDNA's market value added in a single session — points to a significant positive surprise relative to what the market had priced in heading into this earnings release. A revenue figure of $271.4 million for a single quarter is substantial for a company of CareDx's profile in transplant care, and the continued narrowing of losses relative to revenue scale is the narrative investors appear to be rewarding.

That said, the company remains unprofitable at the operating level. An operating loss of $24.7 million against $271.4 million in revenue represents an operating margin of roughly -9%, meaning cost discipline and operating leverage remain the central story for the path to profitability. Investors should watch for management's commentary on the trajectory of operating expenses, gross margins, and any updated forward guidance included in the full 10-Q filing.

The fact that today's price move carries CDNA above prior analyst targets reflects how quickly market sentiment can shift in response to earnings surprises — and reinforces why updated coverage assessments following new filings are important for investors tracking this name.

Disclaimer

This report is a news and informational summary based solely on data extracted from CareDx's official SEC filing and XBRL-reported financial facts. It does not constitute investment advice, an equity research recommendation, or a solicitation to buy or sell any security. No rating or price target is issued or implied herein. Investors should conduct their own due diligence and consult a qualified financial adviser before making investment decisions.

Existing Coverage

StockWatch has full coverage on CDNA, published 2026-09-24. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-10-29. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1217234/000121723426000061/cdna-20260930.htm